Charles River Laboratories International, Inc. (CRL)
| Market Cap | 16.19B +91.9% |
| Revenue (ttm) | 3.98B -1.2% |
| Net Income | 40.19M |
| EPS | 0.83 |
| Shares Out | 47.92M |
| PE Ratio | 407.86 |
| Forward PE | 26.49 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 838,318 |
| Open | 342.18 |
| Previous Close | 340.81 |
| Day's Range | 333.04 - 342.58 |
| 52-Week Range | 146.20 - 379.63 |
| Beta | 1.34 |
| Analysts | Buy |
| Price Target | 350.57 (+3.73%) |
| Earnings Date | Nov 4, 2026 |
About CRL
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, ins... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for CRL stock is "Buy." The 12-month stock price target is $350.57, which is an increase of 3.73% from the latest price.
News
Charles River announces investments, enhancements across Microbial Solutions
Charles River (CRL) Laboratories has announced a series of strategic investments and operational enhancements across its global Microbial Solutions network designed to strengthen the infrastructure th...
Charles River Strengthens Global Microbial Solutions Network Through Investments in Manufacturing, Customer Support, and Sustainability
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River has announced a series of strategic investments and operational enhancements across its global Microbial Solutions network.
Charles River, Toxys to broaden access to ToxTracker, ReproTracker
Toxys and Charles River (CRL) Laboratories announced an expanded collaboration to broaden access to ToxTracker and ReproTracker, two New Approach Methodologies for genotoxicity and developmental toxic...
Charles River price target raised to $388 from $325 at TD Cowen
TD Cowen analyst Charles Rhyee raised the firm’s price target on Charles River (CRL) to $388 from $325 and keeps a Buy rating on the shares. The firm updated the…
Tigermed to Participate in the Privatization of Frontage Holdings Corporation and Divest Its Overseas Laboratory Services Business
HANGZHOU, China, Nov. 10, 2026 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. (Stock Codes: 300347.SZ / 3347.HK, hereinafter referred to as "Tigermed"), a leading global provider of integrated...
Charles River to acquire Frontage’s bioanalysis and DMPK businesses for $470M
Charles River (CRL) Laboratories announced that it has entered into definitive agreements to acquire Frontage Holdings’ bioanalysis and DMPK operations in Exton, Pennsylvania for approximately $470M i...
Charles River Laboratories to Acquire Frontage's Bioanalysis and DMPK Businesses
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories to Acquire Frontage's Bioanalysis and DMPK Businesses.
Charles River price target raised to $315 from $295 at Mizuho
Mizuho analyst Ann Hynes raised the firm’s price target on Charles River (CRL) to $315 from $295 and keeps a Neutral rating on the shares.
Charles River price target raised to $352 from $322 at RBC Capital
RBC Capital raised the firm’s price target on Charles River (CRL) to $352 from $322 and keeps an Outperform rating on the shares. The company reported a solid Q3 beat…
Charles River price target raised to $387 from $357 at UBS
UBS raised the firm’s price target on Charles River (CRL) to $387 from $357 and keeps a Buy rating on the shares.
Charles River price target raised to $364 from $334 at Baird
Baird raised the firm’s price target on Charles River (CRL) to $364 from $334 and keeps an Outperform rating on the shares.
Charles River price target raised to $375 from $330 at Barclays
Barclays raised the firm’s price target on Charles River (CRL) to $375 from $330 and keeps an Overweight rating on the shares post the Q3 report. The company has improved…
Charles River price target raised to $400 from $330 at Evercore ISI
Evercore ISI raised the firm’s price target on Charles River (CRL) to $400 from $330 and keeps an Outperform rating on the shares. With stronger bookings now translating into meaningful…
Charles River Laboratories International Earnings Call Transcript: Q3 2026
Q3 organic revenue rose 4.7% and non-GAAP EPS grew 27.2%, beating prior outlook. FY26 revenue and EPS guidance increased on improving demand, strong DSA bookings and manufacturing recovery.
Charles River Laboratories International Earnings release: Q3 2026
Charles River Laboratories International released its Q3 2026 earnings on November 4, 2026, summarizing the period's financial results.
Charles River Laboratories International Slides: Q3 2026
Charles River Laboratories International has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 4, 2026.
Charles River Laboratories International Quarterly report: Q3 2026
Charles River Laboratories International has published its Q3 2026 quarterly earnings report on November 4, 2026.
Charles River Laboratories Announces Third-Quarter 2026 Results
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces Third-Quarter 2026 Results.
Charles River leverages Virtual Control Groups in GLP studies
Charles River (CRL) Laboratories International announced that its Virtual Control Group, VCG, database and methodology, aimed at reducing animal use, will be used in an upcoming Good Laboratory Practi...
Charles River Leverages Virtual Control Groups in GLP Studies
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River announces that its VCG database and methodology, designed to reduce animal use, will be used in an upcoming GLP study for Ipsen.
Charles River, Labcorp, FDA to partner on study of drug abuse potential
Charles River (CRL) Laboratories announced a Research Collaboration Agreement with the U.S. Food and Drug Administration (FDA) and Labcorp for developing sensitive screening tools to quantify and rank...
Labcorp, Charles River and FDA to collaborate to evaluate drug abuse potential
Labcorp (LH) announced a collaboration with the FDA and Charles River Laboratories (CRL) to advance the science used to evaluate a medicine’s abuse potential, or the likelihood that it could…
Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River announced a collaboration with the U.S. FDA and Labcorp to develop screening tools to quantify and rank the abuse potential of new...
Charles River announces collaboration with Magellan Stem Cells
Charles River (CRL) Laboratories and Magellan Stem Cells announce their collaboration to support Magellan in the development and clinical advancement of its proprietary stem cell-based therapies and r...
Charles River Collaborates with Magellan Stem Cells to Advance Stem Cell and Regenerative Medicine Development
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) and Magellan Stem Cells, a private Australian biotech and cell-therapy firm, announce thei...